Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

@article{Kreiter2010IntranodalVW,
  title={Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.},
  author={Sebastian Kreiter and Abderraouf Selmi and Mustafa Diken and Michael Koslowski and Cedrik M. Britten and Christoph Huber and O. T{\"u}reci and Uğur Şahin},
  journal={Cancer research},
  year={2010},
  volume={70 22},
  pages={
          9031-40
        }
}
Although naked antigen-encoding RNA has entered clinical testing, basic knowledge on how to apply this promising novel vaccine format is still pending. By comparing different administration routes, we observed surprisingly potent antigen-specific T-cell immunity upon intranodal injection of naked antigen-encoding RNA. RNA was selectively uptaken by resident dendritic cells, propagated a T-cell attracting and stimulatory intralymphatic milieu, and led to efficient expansion of antigen-specific… 
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.
TLDR
It is shown that RNA vaccination can be optimized by coadministration of the DC-activating Fms-like tyrosine kinase 3 (FLT3) ligand as an effective adjuvant as well as improving the simple and safe strategy offered by RNA vaccines for cancer immunotherapy.
FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.
TLDR
Methods for intranodal immunization with naked mRNA by co-administration of FLT3 ligand are described, which leads to strong synergistic effects.
Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice
TLDR
These findings suggest that intranodal vaccination with NP mRNA induces cross-strain immunity against influenza, but also highlight a paradox of influenza immunity, whereby robust immune responses can provide protection, but can also transiently exacerbate symptoms during infection.
Clinical and immunological effects of mRNA vaccines in malignant diseases
TLDR
This review will summarize the most recent technological developments and application of mRNA vaccines in clinical trials and discusses the results, challenges and future directions with a special focus on the induced innate and adaptive immune responses.
A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice
TLDR
CD4 neoantigen vaccine/LRT treatment followed by anti-CTLA-4 antibody therapy further enhanced the efficacy with complete remission of gp70-negative CT26 tumors and survival of all mice, highlighting the power of combining synergistic modes of action.
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation
TLDR
It is observed that RNA is rapidly and selectively uptaken by lymph node dendritic cells (DCs), implying that bioavailability of recombinant RNA vaccines in vivo highly depends on the density and the maturation stage of DCs at the administration site and are of importance for the design of RNA-based clinical immunotherapy protocols.
Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.
TLDR
It is demonstrated that SV vectors carrying a TAA generate a dramatically enhanced therapeutic effect in mice bearing subcutaneous, intraperitoneal, and lung cancers and proposed a model for CD8+ T-cell activation during SV/TAA therapy.
Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice
TLDR
It is demonstrated that direct antigen translation by dermal DCs after intradermal naked RNA vaccination is relevant for efficient priming of antigen-specific T-cells.
mRNA Vaccination and Personalized Cancer Therapy
TLDR
This chapter provides a short summary of the history of mRNA-based vaccination and introduces into the design and production of mRNA vaccines, and provides insights into the preclinical development and clinical translation of personalized mRNA vaccines which are tailored to the antigen profile of individual cancer patients.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
TLDR
The finding that RNA transcribed in vitro from cDNA cloned in a bacterial plasmid was highly effective in sensitizing DC shows that amplification of the antigenic content from a small number of tumor cells is feasible, thus expanding the potential use of RNA-pulsed DC- based vaccines for patients bearing very small, possibly microscopic, tumors.
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
TLDR
It is shown here that direct injection of protamine-protected mRNA is feasible and safe and the significant influence of the treatment on the frequency of immunosuppressive cells, the increase of vaccine-directed T cells upon treatment in a subset of patients together with the demonstration of a complete clinical response encourage further clinical investigation of the protamines-mRNA vaccine.
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
TLDR
It is demonstrated here that such treatment is feasible and safe (phase 1 criteria) and an increase in antitumor humoral immune response was seen in some patients, however, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumors immunotherapy was not shown in this study and must be evaluated in subsequent trials.
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo
TLDR
5′ mRNA cap analogs are established as yet another module for tuning immunopharmacological properties of recombinant antigen-encoding RNA for vaccination purposes by analyzing the effect of different synthetic 5′ mRNAcap analogs on the kinetics of the encoded protein.
Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines
TLDR
It is reported here that injection of naked β-globin untranslated region (UTR)-stabilized mRNA coding for β-galactosidase is followed by detectable translation in vivo, and it is shown that such a vaccination strategy primes a T helper 2 type of response which can be enhanced and shifted to a Th1-type immune response by application of recombinant granulocyte/macrophage colony-stimulating factor 1 day after mRNA injection.
Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA
TLDR
RNA molecules are potent and safe danger signals that are relevant for active immunotherapy strategies aimed at the eradication of solid tumors, and are shown to induce tumor regression and long‐term anti‐tumor immunity.
Cancer immunotherapy with mRNA‐transfected dendritic cells
TLDR
Immunization with mRNA‐transfected DCs is a promising strategy to stimulate potent antitumor immunity and could serve as a foundation for developing effective treatments for cancer.
...
...